Monday, July 14, 2014 1:19:38 PM
The Thing to Remember Is This....
Their CEO is coming from a previous pump & dump company, VelaTel Global. Now worth .0004 cents
Their Chairwoman is a pump & dumper. efoodsafety got dumped down to 2 pennies before they changed the name to Nuvilex.
Their Investor Relations executive was convicted of stock fraud, manipulation, breach of trust and more. Check the FINRA report for Marlin Molinaro.
Their 'new technology' dates back to 1996. Phase 2's were already done in 1999 and Orphan Status was given to Austrianova in 2003. Nothing came of it.
If this 'revolutionary technology' is so valuable, why were the licenses then sold to Nuvilex for shares of penny stock?
Nuvilex as a formal company has been in business for 5 years. They have been touting Cell-in a Box for over 3. But yet the current talk is about pre-clinical studies. And in those 5 they have yet to generate any revenue and the only formal large investments they have attracted have been from Toxic Financing corporations.
Combine the pump & dump management factors with the track history of stagnation and no revenues and you are looking at a prolonged campaign of continued carrot dangling meant to keep the share price stable, so management can cash out at your expense.
Caveat Emptor.
Their CEO is coming from a previous pump & dump company, VelaTel Global. Now worth .0004 cents
Their Chairwoman is a pump & dumper. efoodsafety got dumped down to 2 pennies before they changed the name to Nuvilex.
Their Investor Relations executive was convicted of stock fraud, manipulation, breach of trust and more. Check the FINRA report for Marlin Molinaro.
Their 'new technology' dates back to 1996. Phase 2's were already done in 1999 and Orphan Status was given to Austrianova in 2003. Nothing came of it.
If this 'revolutionary technology' is so valuable, why were the licenses then sold to Nuvilex for shares of penny stock?
Nuvilex as a formal company has been in business for 5 years. They have been touting Cell-in a Box for over 3. But yet the current talk is about pre-clinical studies. And in those 5 they have yet to generate any revenue and the only formal large investments they have attracted have been from Toxic Financing corporations.
Combine the pump & dump management factors with the track history of stagnation and no revenues and you are looking at a prolonged campaign of continued carrot dangling meant to keep the share price stable, so management can cash out at your expense.
Caveat Emptor.
Recent PMCB News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:17:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:17:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:17:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:16:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:19:59 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/17/2026 07:49:54 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/09/2026 01:40:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/09/2026 10:02:46 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/27/2026 10:05:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/07/2026 10:43:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/07/2026 10:43:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/18/2025 10:04:23 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 12/15/2025 09:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/12/2025 10:07:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2025 10:00:25 PM
- PharmaCyte Biotech stock surges following profitable exit from Femasys investment • IH Market News • 11/25/2025 03:56:47 PM
- PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment • Business Wire • 11/25/2025 02:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/18/2025 09:32:29 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/18/2025 09:05:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 08:05:33 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/06/2025 09:08:43 PM
